SNTI Senti Biosciences Holdings, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1854270 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY51.2%
Revenue 3-yr CAGR-69.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-67,652.7%
Net margin-58,140.5%
FCF margin—
EBITDA margin-63,736.5%
Returns
ROE—
ROA-106.2%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets133.9%
Debt / equity—
Current ratio0.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-19.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $22,000 | $0 | $2.56M | $4.29M | $2.76M |
| R&D expense | $37.59M | $34.36M | $32.15M | $28.14M | $21.96M |
| SG&A expense | $26.16M | $26.37M | $37.18M | $38.23M | $21.25M |
| Operating income | -$68.78M | -$61.04M | -$92.73M | -$62.08M | -$40.45M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$61.44M | -$52.79M | -$71.06M | -$58.21M | -$55.32M |
| EBITDA | -$65.14M | -$57.20M | -$89.17M | -$60.68M | -$39.68M |
| EPS (basic) | -2.73 | -12.03 | -16.01 | -2.23 | -19.00 |
| EPS (diluted) | -2.73 | -12.03 | -16.01 | -2.23 | -19.00 |
| Weighted avg. shares (diluted) | 22.48M | 4.60M | 4.44M | 26.11M | 2.91M |
| Balance sheet | |||||
| Cash & equivalents | $16.42M | $51.81M | $39.45M | $60.99M | $59.29M |
| Short-term investments | — | — | $0 | $40.94M | $0 |
| Receivables | — | — | — | $626,000 | $483,000 |
| Current assets | $23.27M | $58.96M | $71.20M | $102.58M | $60.19M |
| PP&E, net | $12.89M | $21.29M | $25.34M | $51.36M | $12.37M |
| Total assets | $51.22M | $97.84M | $119.48M | $180.79M | $96.70M |
| Current liabilities | $13.97M | $13.15M | $12.67M | $18.05M | $14.54M |
| Total liabilities | $45.63M | $47.09M | $52.57M | $53.53M | $36.33M |
| Shareholders' equity | $5.59M | $25.65M | $66.91M | $127.26M | -$111.46M |
| Shares outstanding | 30.88M | 4.83M | 4.57M | 44.06M | 2.97M |
| Cash flow statement | |||||
| Operating cash flow | -$43.44M | -$41.40M | -$52.40M | -$34.90M | -$34.63M |
| Capital expenditure | $196,000 | $26,000 | $12.04M | $41.37M | $5.54M |
| Free cash flow | -$43.64M | -$41.42M | -$64.43M | -$76.27M | -$40.18M |
| Investing cash flow | -$184,000 | $34,000 | $30.08M | -$81.96M | -$5.54M |
| Financing cash flow | $11.76M | $53.73M | $779,000 | $118.55M | $68.44M |
| Depreciation & amortization | $3.64M | $3.84M | $3.56M | $1.40M | $769,000 |
| Stock-based compensation | $5.71M | $1.75M | $9.67M | $16.39M | $2.29M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.